Lundbeck has launched the first sublingual treatment for bipolar I disorder, also known as manic depression, in the UK.
Sycrest (asenapine) is a new type of antipsychotic that stabilises manic episodes and has been shown to cause less weight gain than standard antipsychotic drugs such as olanzapine.
The launch accompanies the publication of a study showing that over three-quarters of patients taking antipsychotics suffer unwanted weight gain, and nearly half consider their medication unsatisfactory.
Bipolar disorder affects an estimated 623,000 patients in the UK, including many high-performing professionals.
Monday, January 16, 2012
Asenapine for manic depression launched in UK
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment